Immunogenic compositions in particulate form and methods for producing the same

摘要

The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumor origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium.

主权项

1. An immunogenic composition in particulate form, comprising:
i. a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium as particulate carrier; ii. oligomers of a recombinantly produced polypeptide attached non-covalently to said BLP, wherein the recombinant polypeptide comprises:
A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused toB) an oligomerization domain (OMD), said oligomerization domain being fused viaC) a linker domain toD) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain mediating the non-covalent attachment of the polypeptide to the BLP, and wherein the polypeptide as a whole contains only a single copy of a LysM domain; and iii. a pharmaceutically acceptable diluent or excipient.